STOCK TITAN

Notifications

Limited Time Offer! Get Platinum at the Gold price until January 31, 2026!

Sign up now and unlock all premium features at an incredible discount.

Read more on the Pricing page

Agilent Technologies Inc Stock Price, News & Analysis

A NYSE

Welcome to our dedicated page for Agilent Technologies news (Ticker: A), a resource for investors and traders seeking the latest updates and insights on Agilent Technologies stock.

Agilent Technologies Inc (A) delivers cutting-edge analytical instruments and laboratory solutions for scientific advancement across biopharmaceutical, diagnostic, and environmental sectors. This page provides investors and industry professionals with a centralized source for all official company announcements and market-relevant developments.

Access real-time updates on Agilent's financial performance, strategic partnerships, product innovations, and regulatory milestones. Our curated news collection includes earnings releases, executive leadership updates, R&D breakthroughs, and industry event coverage—all essential for tracking the company's impact on life sciences and laboratory technology.

Key focus areas include advancements in genomic research tools, sustainability initiatives in lab operations, and cross-sector collaborations driving scientific discovery. Bookmark this page to stay informed about Agilent's evolving role in enabling precision medicine, environmental testing, and next-generation materials analysis.

Rhea-AI Summary

Agilent Technologies Inc. (NYSE: A) has announced its definitive agreement to acquire Resolution Bioscience Inc. for $550 million in cash, with an additional $145 million based on performance milestones. This acquisition enhances Agilent’s capabilities in next-generation sequencing (NGS)-based precision oncology solutions, aiming to expand access to cancer diagnostics. Resolution Bioscience, known for its noninvasive liquid biopsy assay and FDA-designated HRD assay, reported revenues of approximately $35 million in 2020 and is projected to earn $50-55 million this year. The deal is expected to close in April.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.67%
Tags
-
Rhea-AI Summary

Agilent Technologies Inc. (NYSE: A) announced the recipient of the 2021 Darlene Solomon Award, Noemi Jiménez-Rojo, a postdoctoral fellow at the University of Geneva. The award aims to support early-career scientists in mass spectrometry research and is co-sponsored by Agilent and Females in Mass Spectrometry (FeMS). Dr. Jiménez-Rojo will participate in mass spectrometry conferences and work at Agilent's Global Solutions Development Center in Singapore, gaining practical experience and mentorship opportunities.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.67%
Tags
none
-
Rhea-AI Summary

Agilent Technologies Inc. (NYSE: A) announced FDA approval for its PD-L1 IHC 22C3 pharmDx assay, expanding its application to non-small cell lung cancer (NSCLC) patients with tumor PD-L1 expression of Tumor Proportion Score (TPS) ≥ 50%. This diagnostic aids in identifying eligibility for treatment with Libtayo® (cemiplimab-rwlc), an anti-PD-1 therapy. Agilent's assay is the only FDA-approved companion diagnostic for this purpose, enhancing pathologist confidence in patient assessments and reinforcing Agilent's leadership in companion diagnostics for cancer therapies.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.66%
Tags
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.63%
Tags
none
-
Rhea-AI Summary

Agilent Technologies Inc. (NYSE: A) has launched the Agilent Dako SARS-CoV-2 IgG ELISA kit, enabling qualitative detection of IgG antibodies to SARS-CoV-2 in human serum or plasma. This marks Agilent's entry into SARS-CoV-2 testing in the US, following FDA notification. The kit boasts an impressive 98.9% sensitivity and 98.8% specificity and includes all necessary reagents for ease of use in small to medium-sized clinical labs. Agilent aims to expand this offering globally, supporting COVID-19 management with additional tests planned, including a quantitative RT-PCR test.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.88%
Tags
none
-
Rhea-AI Summary

Agilent Technologies Inc. (NYSE: A) has launched the Seahorse XF HS Mini Analyzer, enhancing metabolic analysis capabilities for researchers using rare and genetically engineered cells. This new device offers improved sensitivity and requires fewer cells per well, making it ideal for low respiring cell types like immune cells. As researchers focus on complex in vivo settings, the XF HS Mini promises to unlock advanced metabolic analyses, thereby increasing the utility of Agilent’s technology in disease modeling.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.7%
Tags
none
Rhea-AI Summary

Agilent Technologies reported a revenue of $1.55 billion for Q1 2021, marking a 14% increase year-over-year and a 11% rise on a core basis. GAAP net income surged to $288 million (93 cents/share), up from $197 million (63 cents/share) in Q1 2020. Non-GAAP net income was $328 million (1.06/share), compared to $252 million (81 cents/share) the previous year. Agilent raised its full-year revenue outlook to $5.825 billion - $5.900 billion and announced a new $2 billion share repurchase program, effective Feb. 18.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.7%
Tags
-
Rhea-AI Summary

Agilent Technologies (NYSE: A) has announced key webcasts for the investment community. The 10th Annual SVB Leerink Global Healthcare Conference is scheduled for Feb. 24 at 7:40 a.m. PT, featuring CFO Bob McMahon. Following this, the 41st Annual Cowen And Company Healthcare Conference will take place on March 4 at 8:10 a.m. PT, with President and CEO Mike McMullen presenting. Additionally, Agilent's Annual Shareholder Meeting is set for March 17 at 8 a.m. PT, with virtual access starting at 7:30 a.m. PT.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.19%
Tags
conferences
-
Rhea-AI Summary

Agilent Technologies (NYSE: A) won a federal court judgement in Texas against Shanghai's J&X Technologies for patent infringement and trade secret misappropriation. J&X must pay over $1.25 million for using Agilent's proprietary gas chromatography technology. The court's ruling also prohibits J&X and its founders from manufacturing or selling related products and from disclosing Agilent's proprietary information. This victory underscores Agilent’s commitment to protecting its intellectual property as it continues to innovate in gas chromatography.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.55%
Tags
none
Rhea-AI Summary

Agilent Technologies Inc. (NYSE: A) will announce its first-quarter fiscal year 2021 financial results following the market close on February 16, 2021. A live webcast of the investor conference call will take place at 1:30 p.m. Pacific time on the same day. Agilent generated $5.34 billion in revenue during fiscal year 2020 and employs approximately 16,400 individuals worldwide. The webcast will be accessible for 90 days on the company's website.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.24%
Tags
conferences earnings

FAQ

What is the current stock price of Agilent Technologies (A)?

The current stock price of Agilent Technologies (A) is $146.87 as of November 14, 2025.

What is the market cap of Agilent Technologies (A)?

The market cap of Agilent Technologies (A) is approximately 41.6B.
Agilent Technologies Inc

NYSE:A

A Rankings

A Stock Data

41.64B
282.61M
0.29%
92.62%
1.07%
Diagnostics & Research
Laboratory Analytical Instruments
Link
United States
SANTA CLARA